Paper Details

  1. Home
  2. Paper Details

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Author: , AndersonKenneth C, ArnulfBertrand, AttalMichel, Avet-LoiseauHervé, BelhadjKarim, CaillotDenis, EscoffreMartine, FaconThierry, FermandJean P, GarderetLaurent, HarousseauJean-Luc, HulinCyrille, Lauwers-CancesValerie, LeleuXavier, MacroMargaret, MaglioMichelle E, MathiotClaire, MeulemanNathalie, MoreauPhilippe, MunshiNikhil, PayenCatherine, RichardsonPaul G, RolletSandrine, RousselMurielle, WellerEdie A, ZeytoonjianAndrea A

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

High-dose chemotherapy followed by a stem cell transplant has been the standard treatment for newly diagnosed multiple myeloma in adults under 65. However, promising results with a combination of lenalidomide, bortezomib, and dexamethasone (RVD) have raised questions about the role and timing of stem cell transplants in treating this type of cancer.
Paper Details　
Original Abstract of the Article :
High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this population h...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28379796

データ提供：米国国立医学図書館（NLM）

Lenalidomide, Bortezomib, and Dexamethasone for Multiple Myeloma: A New Path in Treatment

The battle against multiple myeloma, a type of blood cancer, is a continuous quest for effective and safe therapies. This research investigates the potential of a combination therapy using lenalidomide, bortezomib, and dexamethasone (RVD) in the treatment of newly diagnosed multiple myeloma in adults. This combination therapy has shown promising results and is now being considered as a potential alternative to high-dose chemotherapy followed by autologous stem-cell transplantation, a treatment regimen that has been the standard for many years.

A Potential Shift in the Treatment Landscape

The study's findings suggest that RVD therapy could potentially become a standard treatment for newly diagnosed multiple myeloma in adults. This could be a significant shift in the treatment landscape, offering patients a potentially less invasive and more effective alternative to traditional therapies. The research highlights the importance of exploring new treatment combinations and staying at the forefront of medical advancements.

Navigating the Desert of Multiple Myeloma Treatment

The research into RVD therapy offers a glimmer of hope for those battling multiple myeloma. This new combination therapy provides a potentially effective and less invasive approach, offering a path towards a more manageable journey through this challenging disease. While more research is needed to fully understand its long-term effects, the findings suggest that this combination therapy might be a valuable tool in the fight against multiple myeloma.

Dr.Camel's Conclusion

This research is a beacon of hope in the vast desert of multiple myeloma treatment. The potential of RVD therapy offers a new path for patients, a promising oasis in the fight against this complex disease. The future holds exciting possibilities for new and improved treatments, and this research brings us one step closer to conquering this challenging terrain.

Date :
  1. Date Completed 2017-04-27
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

28379796

DOI: Digital Object Identifier

NIHMS988972

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.